Clinical Trial Detail

NCT ID NCT02115295
Title Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

acute leukemia

chronic myeloid leukemia

Therapies

Cladribine + Cytarabine + Idarubicin

Midostaurin

Age Groups: adult senior

No variant requirements are available.